Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer (pHART3)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Canadian Association of Radiation Oncology
Information provided by (Responsible Party):
Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT01578902
First received: October 31, 2011
Last updated: October 30, 2013
Last verified: October 2013

October 31, 2011
October 30, 2013
October 2006
October 2013   (final data collection date for primary outcome measure)
Incidence of grade 3+ rectal toxicity [ Time Frame: Acute period (up to 6 months) ] [ Designated as safety issue: Yes ]
Common Terminology Criteria for Adverse Events (CTCAE) v3.0
Same as current
Complete list of historical versions of study NCT01578902 on ClinicalTrials.gov Archive Site
  • Incidence of grade 3+ urinary toxicity [ Time Frame: Acute (up to 6 months) and Late (6 months and after) ] [ Designated as safety issue: Yes ]
    Common Terminology Criteria for Adverse Events (CTCAE) v3.0
  • Incidence of grade 3+ rectal and urinary toxicity [ Time Frame: Late (6 months and after) ] [ Designated as safety issue: Yes ]
    Common Terminology Criteria for Adverse Events (CTCAE) v3.0
  • Quality of Life [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
    Expanded Prostate Cancer Index Composite (EPIC)
  • Biochemical (ie. prostate specific antigen) disease free survival [ Time Frame: 5 year ] [ Designated as safety issue: No ]
  • Biopsy positive rate [ Time Frame: 3 year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer
Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer (pHART 3)

The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (35 Gy / 5 fractions / 29 days) for the treatment of low-risk prostate cancer.

Rationale for Proposed Study With the availability of intensity modulated radiotherapy (IMRT) at the Odette Cancer Centre (OCC), there is an opportunity to explore the use of a much more intensive hypofractionation schedule for prostate cancer. Using an alpha/beta ratio of 1.3, a dose of 35 Gy in 5 fractions would be equivalent to 88 Gy delivered in 2 Gy fractions. For normal tissues (alpha/beta value of 2), this would be equivalent to 78 Gy in 2 Gy fractions. As such, the linear quadratic equation predicts that 35 Gy in 5 fractions should not result in any increased late toxicity for normal tissues compared to standard dose escalated radiotherapy. However, the biological dose to the prostate cancer would be significantly increased. As a safety precaution for this study proposal, the investigators propose to deliver 35 Gy in 5 fractions over 5 weeks (one radiotherapy fraction of 7 Gy per week) to allow for normal tissue repair.

With IMRT, it is expected that there will be superior conformality of the high dose region around the target volume. As well, the use of daily on-line imaging will allow us to eliminate interfraction prostate motion errors and use tighter planning target volume margins for any residual intrafraction motion. At OCC, such an approach has already been shown to be feasible and is currently employed in the phase 1/2 concomitant boost study for high risk prostate cancer.

If proven to be safe and effective, such a hypofractionated radiotherapy schedule may have significant practical advantages as well. With only 1 fraction of radiotherapy delivered each week (for a total of 5 weeks), there are huge savings in resource utilization and increased convenience for patients.

The investigators propose to start a small phase 1 study to explore the use of this dose fractionation for men with low risk prostate cancer. The primary endpoint for this small pilot study would be acute and late normal tissue toxicities. If proven to be feasible and safe, external peer-reviewed funding will be sought to further explore this novel treatment schedule in a larger phase 2 setting.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
Radiation: Hypofractionated radiotherapy
35Gy/5 fractions/29 days
Other Name: standard linear accelerator delivery
Experimental: Hypofractionated radiation
35 Gy in 5 fractions of image-guided intensity modulated radiotherapy (IGRT) delivered over 29 days.
Intervention: Radiation: Hypofractionated radiotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
October 2013
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Informed consent signed (Appendix A)
  • Adult men greater than 18 years of age
  • Histologically confirmed diagnosis of adenocarcinoma of the prostate (centrally reviewed).
  • Clinical stage T1-T2b, Gleason Score < 6, and PSA < 10 ng/mL
  • Less than 50% of biopsy cores +ve for cancer
  • Less than 50% overall surface area involved with cancer
  • Neoadjuvant hormone suppression therapy is allowed. However, PSA, must have been performed within 2 months of starting androgen suppression therapy. If androgen suppression therapy has been started LHRH agonist must be continued for a minimum of 3 months before initiation of gold fiducial marker insertion & radiotherapy planning.

Exclusion Criteria:

  • Prior pelvic radiotherapy.
  • Concurrent anticoagulation medication (if it is unsafe to discontinue for gold seed insertion)
  • Diagnosis of bleeding diathesis
  • Presence of a hip prosthesis
  • Pelvic girth >40cm (to ensure visibility of gold seeds on electronic portal imaging device)
  • Large prostate (> 60 cm3) on imaging
  • Severe lower urinary tract symptoms (International Prostate Symptom Score > 15 or nocturia > 3)
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01578902
1002-2006
Yes
Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Canadian Association of Radiation Oncology
Principal Investigator: Andrew Loblaw, MD Sunnybrook Health Sciences Centre
Principal Investigator: Patrick Cheung, MD Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP